|
CANCERS BRONCHIQUES NON A PETITES CELLULES NON METASTATIQUES NON RESECABLES
CHIMIOTHÉRAPIE D’INDUCTION AVANT IRRADIATION
|
|
Référence |
traitement |
n pts |
RO
(%) |
SM
(mois) |
survie à 2 ans |
p |
Mattson,
1988 |
1. CPA-ADR-CDDP(2x) puis RT (55Gy) |
76 |
49 |
ND |
ND |
S |
2. RT (55Gy) |
78 |
44 |
ND |
ND |
|
|
|
|
|
|
|
Dillman,
1990 |
1. CDDP-VBL(2x) puis RT (60Gy) |
78 |
46 |
13,8 |
26% |
S |
2. RT (60Gy) |
77 |
35 |
9,7 |
13% |
|
|
|
|
|
|
|
Morton,
1991 |
1. MTX-ADR-CPA-CCNU(2x) puis RT (60 Gy) |
56 |
55 |
10,6 |
21% |
NS |
2. RT (60 Gy) |
58 |
64 |
10,4 |
16% |
|
|
|
|
|
|
|
Le Chevalier, 1991 |
1. VDS-CPA-CDDP-CCNU(3x) puis RT (65 Gy) |
176 |
31 |
12 |
21% |
S |
2. RT (65 Gy) |
177 |
35 |
10 |
14% |
|
|
|
|
|
|
|
Gregor,
1993 |
1. CDDP-VDS(2x) puis RT (50 Gy) |
39 |
62 |
12,1 |
ND |
NS |
2. RT (50 Gy) |
39 |
42 |
12,4 |
ND |
|
|
|
|
|
|
|
Crino,
1993 |
1. CDDP-VP16(3x) puis RT (56 Gy) |
29 |
53 |
12,1 |
28% |
NS |
2. RT (56 Gy) |
32 |
32 |
8,4 |
14% |
|
|
|
|
|
|
|
Wolf,
1997 |
1. Ifo-VDS (2x) puis RT (50 Gy) |
37 |
57 |
13,7 |
24 % |
S |
2. RT (50 Gy) |
41 |
41 |
9 |
12 % |
|
|
|
|
|
|
|
Sause,
1995 |
1. CDDP-VBL (2x) puis RT (60 Gy) |
164 |
|
13,8 |
ND |
S |
2. RT (60 Gy) |
163 |
|
11.4 |
ND |
3. RT bifractionnée (69.6 Gy) |
163 |
|
12,3 |
ND |
|
|
|
|
|
|
|
Planting,
1996 |
1. CDDP-VDS (2x) puis RT (55Gy)+ 1 cure CT |
37 |
41 |
12,0 |
|
NS |
2. RT (55 Gy) |
33 |
55 |
12,0 |
|
|
|
|
|
|
|
|
Brodin,
1996 |
1. CDDP-VP16 (2x) puis RT (56 Gy) |
163 |
26 |
11 |
21% |
NS |
2. RT (56 Gy) |
164 |
25 |
10,5 |
17% |
|
|
|
|
|
|
|
Cullen,
1999 |
I. MMC-Ifo-CDDP |
223 |
54 |
12 |
|
NS |
RT |
223 |
|
10 |
|
|
|
|
|
|
|
|
Mattson,
2003 |
I. Docetaxel (x3) puis RT |
134 |
28 |
14,8 |
|
NS |
II. RT |
140 |
|
12,6 |
|
|
|
|
|
|
|
|
Belani,
2005 |
Carbo (AUC 6) + paclitaxel (225) 2 x puis |
|
|
|
|
0,28 |
I. RT 64 Gy (2 Gy/j) |
59 |
22 % |
14,9 m |
24 % |
II. HART 57,6 Gy (1,5 Gy 3x/j pdt 2,5 sem) |
60 |
25 % |
20,3 m |
33 % |
Beslija,
2005 |
I. Cisplatine + gemcitabine puis RT (63 Gy) |
30 |
47 % |
12,5 m |
|
0,067 |
II. RT (63 Gy) |
30 |
27 % |
10 m |
|
Références
(1) Mattson K, Holsti LR, Holsti P, Jakobsson M, Kajanti M, Liippo K et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988; 24(3):477-482.
(2) Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323(14):940-945.
(3) Dillman RO, Herndon J, Seagren SL, Eaton WLJ, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88(17):1210-1215.
(4) Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991; 115(9):681-686.
(5) Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83(6):417-423.
(6) Dautzenberg B, Chastang C, Arriagada R, Le Chevalier T, Belpomme D, Hurdebourcq M et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer 1995; 76(5):779-786.
(7) Gregor A, Macbeth FR, Paul J, Cram L, Hansen HH. Radical radiotherapy and chemotherapy in localized inoperable non-small- cell lung cancer: a randomized trial. J Natl Cancer Inst 1993; 85(12):997-999.
(8) Crino L, Latini P, Meacci M, Corgna E, Maranzano E, Darwish S et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993; 4(10):847-851.
(9) Wolf M, Hans K, Becker H, Hassler R, von Bultzingslowen F, Goerg R et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 1994; 21(3 Suppl 4):42-47.
(10) Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87(3):198-205.
(11) Sause W, Kolesar P, Taylor S, IV, Johnson D, Livingston R, Komaki R et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117(2):358-364.
(12) Planting A, Helle P, Drings P, Dalesio O, Kirkpatrick A, McVie G et al. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 1996; 7(2):139-144.
(13) Brodin O, Nou E, Mercke C, Linden CJ, Lundstrom R, Arwidi A et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Eur J Cancer 1996; 32A(11):1893-1900.
(14) Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R et al. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer: Effects on Survival and Quality of Life. J Clin Oncol 1999; 17(10):3188-3194.
(15) Mattson KV, Abratt RP, Ten Velde G, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 2003; 14(1):116-122.
(16) Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005; 23(16):3760-3767.
(17) Beslija S, Dizdarevic Z, Lomigoric J, Zutic H, Musanovic M, Mehic B et al. Randomized phase II study of induction chemotherapy with gemcitabine plus cisplatin followed by sequential radiotherapy versus radiotherapy alone in patients with stage III non-small cell lung cancer. Journal of BUON 2005; 10:347-355.
|